​

Encompass Health (EHC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EHC Stock Forecast

Encompass Health stock forecast is as follows: an average price target of $107.50 (represents a 13.82% upside from EHC’s last price of $94.45) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

EHC Price Target

The average price target for Encompass Health (EHC) is $107.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $110.00 to $105.00. This represents a potential 13.82% upside from EHC's last price of $94.45.

EHC Analyst Ratings

Buy

According to 6 Wall Street analysts, Encompass Health's rating consensus is 'Buy'. The analyst rating breakdown for EHC stock is 1 'Strong Buy' (16.67%), 5 'Buy' (83.33%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Encompass Health Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 26, 2024Ben HendrixRBC Capital$105.00$96.758.53%11.17%
Sep 25, 2024AJ RiceUBS$110.00$95.2615.47%16.46%
May 22, 2024Frank MorganRBC Capital$95.00$85.8610.65%0.58%
Apr 25, 2024Ann HynesMizuho Securities$95.00$82.8014.73%0.58%
Mar 28, 2024Andrew MokBarclays$101.00$81.7923.49%6.93%
May 03, 2022RBC Capital$85.00$68.2424.56%-10.01%
May 02, 2022Raymond James$85.00$68.8323.49%-10.01%
Apr 29, 2022Credit Suisse$83.00$68.4621.24%-12.12%
Apr 29, 2021Scott FidelStephens$100.00$84.6218.18%5.88%

The latest Encompass Health stock forecast, released on Sep 26, 2024 by Ben Hendrix from RBC Capital, set a price target of $105.00, which represents a 8.53% increase from the stock price at the time of the forecast ($96.75), and a 11.17% increase from EHC last price ($94.45).

Encompass Health Price Target by Period

1M3M12M
# Anlaysts-25
Avg Price Target-$107.50$101.20
Last Closing Price$94.45$94.45$94.45
Upside/Downside-100.00%13.82%7.15%

In the current month, the average price target of Encompass Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Encompass Health's last price of $94.45. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 29, 2024UBSBuyBuyHold
Oct 29, 2024KeyBancOverweightOverweightHold
Oct 29, 2024BarclaysOverweightOverweightHold
Oct 11, 2024Truist FinancialUnderperformUnderperformHold
Oct 10, 2024KeyBancOverweightInitialise
Sep 26, 2024RBC CapitalOutperformOutperformHold
Sep 25, 2024UBSBuyBuyHold
Aug 06, 2024RBC CapitalUnderperformUnderperformHold
Aug 06, 2024StephensBuyBuyHold
Jul 10, 2024StephensStrong BuyStrong BuyHold
Jul 10, 2024BarclaysOverweightOverweightHold
May 22, 2024RBC CapitalOutperformOutperformHold
Apr 25, 2024BarclaysOverweightOverweightHold
Mar 28, 2024StephensBuyBuyHold
Mar 28, 2024BarclaysOverweightOverweightHold
Mar 06, 2024StephensBuyBuyHold
Mar 06, 2024RBC CapitalUnderperformUnderperformHold
Feb 08, 2023StephensOverweightOverweightHold
May 02, 2022Raymond JamesStrong BuyStrong BuyHold

Encompass Health's last stock rating was published by UBS on Oct 29, 2024. The company gave EHC a "Buy" rating, the same as its previous rate.

Encompass Health Financial Forecast

Encompass Health Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$1.21B$1.19B$1.16B$1.14B$1.09B$1.33B$1.33B$1.32B$1.28B$1.29B$1.23B$1.21B$1.17B$1.07B$1.18B$1.18B$1.16B
Avg Forecast$1.63B$1.58B$1.53B$1.56B$1.50B$1.47B$1.42B$1.43B$1.38B$1.33B$1.30B$1.27B$1.24B$1.20B$1.16B$1.14B$1.12B$1.06B$1.34B$1.33B$1.31B$1.31B$1.27B$1.23B$1.21B$1.18B$1.05B$1.20B$1.18B$1.15B
High Forecast$1.63B$1.59B$1.54B$1.57B$1.51B$1.48B$1.42B$1.44B$1.40B$1.33B$1.30B$1.27B$1.24B$1.21B$1.17B$1.15B$1.13B$1.06B$1.34B$1.33B$1.31B$1.31B$1.27B$1.23B$1.21B$1.18B$1.05B$1.20B$1.18B$1.15B
Low Forecast$1.61B$1.57B$1.52B$1.54B$1.49B$1.45B$1.40B$1.42B$1.36B$1.33B$1.30B$1.27B$1.23B$1.19B$1.15B$1.13B$1.11B$1.06B$1.34B$1.33B$1.31B$1.31B$1.27B$1.23B$1.21B$1.18B$1.05B$1.20B$1.18B$1.15B
# Analysts54544348109336109988889999910101099
Surprise %-------------1.01%1.02%1.01%1.01%1.02%0.99%1.01%1.01%0.98%1.01%1.00%1.01%0.99%1.02%0.99%1.01%1.01%

Encompass Health's average Quarter revenue forecast for Dec 23 based on 6 analysts is $1.24B, with a low forecast of $1.23B, and a high forecast of $1.24B. EHC's average Quarter revenue forecast represents a 2.50% increase compared to the company's last Quarter revenue of $1.21B (Sep 23).

Encompass Health EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts54544348109336109988889999910101099
EBITDA-------------$248.20M$260.10M$246.50M$251.70M$207.60M$225.60M$247.40M$229.00M$238.90M$258.00M$247.10M$232.50M$214.80M$151.80M$216.10M$197.80M$227.30M
Avg Forecast$311.83M$303.81M$293.81M$298.79M$287.82M$281.66M$271.68M$275.33M$265.01M$254.84M$249.72M$256.88M$237.36M$229.47M$222.98M$233.53M$271.09M$217.48M$274.26M$212.30M$266.82M$268.38M$259.48M$177.79M$246.20M$241.49M$215.00M$211.02M$240.64M$235.20M
High Forecast$313.52M$305.47M$295.41M$300.41M$289.39M$283.19M$273.16M$276.83M$268.85M$254.90M$249.72M$308.26M$238.66M$231.82M$224.19M$280.23M$325.31M$217.48M$274.26M$254.76M$266.82M$268.38M$259.48M$213.35M$246.20M$241.49M$215.00M$253.22M$240.64M$235.20M
Low Forecast$308.75M$300.82M$290.91M$295.84M$284.98M$278.88M$269.00M$273.42M$261.17M$254.79M$249.72M$205.51M$235.45M$227.83M$220.78M$186.82M$216.87M$217.48M$274.26M$169.84M$266.82M$268.38M$259.48M$142.23M$246.20M$241.49M$215.00M$168.81M$240.64M$235.20M
Surprise %-------------1.08%1.17%1.06%0.93%0.95%0.82%1.17%0.86%0.89%0.99%1.39%0.94%0.89%0.71%1.02%0.82%0.97%

6 analysts predict EHC's average Quarter EBITDA for Dec 23 to be $237.36M, with a high of $238.66M and a low of $235.45M. This is -4.37% lower than Encompass Health's previous annual EBITDA (Sep 23) of $248.20M.

Encompass Health Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts54544348109336109988889999910101099
Net Income-------------$85.30M$91.40M$87.70M$89.40M$85.50M$71.30M$87.50M$115.70M$100.00M$113.30M$107.30M$86.00M$77.70M$33.50M$87.00M$67.60M$97.60M
Avg Forecast$133.92M$130.38M$128.38M$133.61M$119.67M$119.97M$122.11M$122.55M$104.64M$96.19M$103.31M$100.12M$83.32M$80.06M$75.78M$91.02M$108.44M$65.06M$98.47M$82.74M$107.06M$108.13M$99.73M$77.20M$87.10M$75.73M$33.41M$84.95M$85.55M$90.93M
High Forecast$134.87M$131.31M$129.29M$134.55M$120.52M$120.82M$122.97M$127.66M$110.79M$96.24M$103.32M$120.15M$87.34M$87.34M$76.32M$109.22M$130.12M$65.06M$98.47M$99.29M$107.06M$108.13M$101.44M$92.64M$87.10M$75.73M$33.41M$101.94M$85.55M$90.93M
Low Forecast$132.20M$128.71M$126.73M$131.89M$118.13M$118.43M$120.54M$116.43M$100.53M$96.15M$103.31M$80.10M$80.31M$74.86M$74.81M$72.82M$86.75M$65.06M$98.47M$66.20M$107.06M$108.13M$98.02M$61.76M$87.10M$75.73M$33.41M$67.96M$85.55M$90.93M
Surprise %-------------1.07%1.21%0.96%0.82%1.31%0.72%1.06%1.08%0.92%1.14%1.39%0.99%1.03%1.00%1.02%0.79%1.07%

Encompass Health's average Quarter net income forecast for Dec 23 is $83.32M, with a range of $80.31M to $87.34M. EHC's average Quarter net income forecast represents a -2.32% decrease compared to the company's last Quarter net income of $85.30M (Sep 23).

Encompass Health SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts54544348109336109988889999910101099
SG&A-------------$722.60M$705.90M$686.20M$670.30M$655.90M$853.40M$845.30M$841.60M$793.80M$782.60M$746.00M$744.30M$724.30M$715.20M$734.90M$753.10M$735.10M
Avg Forecast$818.07M$797.06M$770.81M$783.87M$755.09M$738.92M$712.75M$722.33M$695.26M$668.58M$655.14M$967.23M$622.72M$602.03M$584.99M$879.30M$996.29M$535.90M$675.80M$799.36M$657.48M$661.31M$639.38M$536.76M$606.66M$595.07M$529.78M$717.61M$592.96M$579.55M
High Forecast$822.53M$801.40M$775.00M$788.13M$759.20M$742.95M$716.63M$726.26M$705.34M$668.74M$655.14M$1.16B$626.11M$608.18M$588.17M$1.06B$1.20B$535.90M$675.80M$959.23M$657.48M$661.31M$639.38M$644.11M$606.66M$595.07M$529.78M$861.13M$592.96M$579.55M
Low Forecast$810.01M$789.20M$763.21M$776.13M$747.64M$731.64M$705.72M$717.31M$685.18M$668.43M$655.14M$773.78M$617.70M$597.72M$579.22M$703.44M$797.04M$535.90M$675.80M$639.49M$657.48M$661.31M$639.38M$429.40M$606.66M$595.07M$529.78M$574.09M$592.96M$579.55M
Surprise %-------------1.20%1.21%0.78%0.67%1.22%1.26%1.06%1.28%1.20%1.22%1.39%1.23%1.22%1.35%1.02%1.27%1.27%

Encompass Health's average Quarter SG&A projection for Dec 23 is $622.72M, based on 6 Wall Street analysts, with a range of $617.70M to $626.11M. The forecast indicates a -13.82% fall compared to EHC last annual SG&A of $722.60M (Sep 23).

Encompass Health EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts54544348109336109988889999910101099
EPS-------------$0.85$0.91$0.88$0.89$0.86$0.72$0.88$1.17$1.01$1.14$1.08$0.87$0.78$0.34$0.88$0.69$0.99
Avg Forecast$1.31$1.28$1.26$1.31$1.17$1.18$1.20$1.20$1.02$0.94$1.01$0.94$0.82$0.78$0.74$0.70$0.83$0.64$0.97$0.91$1.05$1.06$0.98$0.82$0.85$0.74$0.33$0.84$0.84$0.89
High Forecast$1.32$1.29$1.27$1.32$1.18$1.18$1.20$1.25$1.09$0.94$1.01$0.94$0.86$0.86$0.75$0.71$0.84$0.64$0.97$0.91$1.05$1.06$0.99$0.82$0.85$0.74$0.33$0.84$0.84$0.89
Low Forecast$1.29$1.26$1.24$1.29$1.16$1.16$1.18$1.14$0.98$0.94$1.01$0.94$0.79$0.73$0.73$0.70$0.82$0.64$0.97$0.91$1.05$1.06$0.96$0.82$0.85$0.74$0.33$0.84$0.84$0.89
Surprise %-------------1.08%1.23%1.25%1.07%1.35%0.75%0.96%1.11%0.95%1.17%1.31%1.02%1.05%1.04%1.04%0.82%1.11%

According to 6 Wall Street analysts, Encompass Health's projected average Quarter EPS for Dec 23 is $0.82, with a low estimate of $0.79 and a high estimate of $0.86. This represents a -3.99% decrease compared to EHC previous annual EPS of $0.85 (Sep 23).

Encompass Health Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
SEMSelect Medical$19.12$40.00109.21%Buy
ACHCAcadia Healthcare Company$39.64$81.50105.60%Buy
MODVModivCare$14.10$27.3393.83%Buy
INNVInnovAge$4.08$6.8066.67%Hold
PNTGPennant Group$29.21$34.6718.69%Buy
EHABEnhabit$8.29$9.5014.60%Hold
ENSGEnsign Group$140.00$159.0013.57%Buy
ADUSAddus HomeCare$130.73$146.2011.83%Buy
EHCEncompass Health$96.94$107.5010.89%Buy

EHC Forecast FAQ

Is Encompass Health a good buy?

Yes, according to 6 Wall Street analysts, Encompass Health (EHC) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of EHC's total ratings.

What is EHC's price target?

Encompass Health (EHC) average price target is $107.5 with a range of $105 to $110, implying a 13.82% from its last price of $94.45. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Encompass Health stock go up soon?

According to Wall Street analysts' prediction for EHC stock, the company can go up by 13.82% (from the last price of $94.45 to the average price target of $107.5), up by 16.46% based on the highest stock price target, and up by 11.17% based on the lowest stock price target.

Can Encompass Health stock reach $140?

EHC's average twelve months analyst stock price target of $107.5 does not support the claim that Encompass Health can reach $140 in the near future.

What are Encompass Health's analysts' financial forecasts?

Encompass Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.82B (high $5.85B, low $5.77B), average EBITDA is $1.12B (high $1.12B, low $1.11B), average net income is $484.3M (high $491.97M, low $473.54M), average SG&A $2.93B (high $2.95B, low $2.9B), and average EPS is $4.74 (high $4.82, low $4.64). EHC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $6.3B (high $6.33B, low $6.23B), average EBITDA is $1.21B (high $1.21B, low $1.2B), average net income is $526.28M (high $530.01M, low $519.54M), average SG&A $3.17B (high $3.19B, low $3.14B), and average EPS is $5.15 (high $5.19, low $5.09).

Did the EHC's actual financial results beat the analysts' financial forecasts?

Based on Encompass Health's last annual report (Dec 2022), the company's revenue was $4.35B, which missed the average analysts forecast of $4.86B by -10.43%. Apple's EBITDA was $871.5M, missing the average prediction of $975.13M by -10.63%. The company's net income was $271M, missing the average estimation of $354.71M by -23.60%. Apple's SG&A was $2.6B, missing the average forecast of $3.01B by -13.47%. Lastly, the company's EPS was $2.72, missing the average prediction of $3.35 by -18.75%. In terms of the last quarterly report (Sep 2023), Encompass Health's revenue was $1.21B, beating the average analysts' forecast of $1.2B by 0.91%. The company's EBITDA was $248.2M, beating the average prediction of $229.47M by 8.16%. Encompass Health's net income was $85.3M, beating the average estimation of $80.06M by 6.55%. The company's SG&A was $722.6M, beating the average forecast of $602.03M by 20.03%. Lastly, the company's EPS was $0.85, beating the average prediction of $0.784 by 8.40%